
Abeona Therapeutics Inc. (NASDAQ:ABEO – Free Report) – Equities researchers at HC Wainwright increased their FY2026 earnings estimates for Abeona Therapeutics in a research report issued to clients and investors on Thursday, November 12th. HC Wainwright analyst R. Selvaraju now expects that the biopharmaceutical company will post earnings per share of ($0.96) for the year, up from their previous estimate of ($1.15). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($0.97) per share. HC Wainwright also issued estimates for Abeona Therapeutics’ Q4 2026 earnings at ($0.22) EPS, Q1 2027 earnings at ($0.24) EPS, Q2 2027 earnings at ($0.22) EPS, Q3 2027 earnings at ($0.20) EPS, Q4 2027 earnings at ($0.17) EPS and FY2027 earnings at ($0.82) EPS.
Several other brokerages have also commented on ABEO. Roth Capital initiated coverage on Abeona Therapeutics in a research report on Thursday, September 17th. They issued a “buy” rating and a $17.00 target price for the company. Cantor Fitzgerald increased their target price on shares of Abeona Therapeutics from $28.00 to $30.00 and gave the stock an “overweight” rating in a report on Friday, September 18th. Weiss Ratings downgraded shares of Abeona Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Tuesday, November 10th. UBS Group reaffirmed a “buy” rating on shares of Abeona Therapeutics in a report on Friday, September 25th. Finally, Wall Street Zen raised shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Abeona Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $21.00.
Abeona Therapeutics Price Performance
Shares of NASDAQ ABEO opened at $2.42 on Monday. The stock’s 50 day moving average price is $4.70 and its two-hundred day moving average price is $5.39. Abeona Therapeutics has a 52-week low of $2.09 and a 52-week high of $7.65. The stock has a market capitalization of $138.30 million, a P/E ratio of -2.26 and a beta of 1.50.
Abeona Therapeutics (NASDAQ:ABEO – Get Free Report) last posted its quarterly earnings results on Monday, November 9th. The biopharmaceutical company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.09. The business had revenue of $13.49 million during the quarter, compared to the consensus estimate of $14.82 million. Abeona Therapeutics had a negative return on equity of 44.82% and a negative net margin of 160.30%.
Insiders Place Their Bets
In related news, CFO Joseph Vazzano sold 9,191 shares of the business’s stock in a transaction that occurred on Tuesday, September 29th. The stock was sold at an average price of $5.16, for a total transaction of $47,425.56. Following the completion of the transaction, the chief financial officer owned 482,888 shares in the company, valued at $2,491,702.08. The trade was a 1.87% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Vishwas Seshadri sold 19,608 shares of the business’s stock in a transaction that occurred on Tuesday, September 29th. The shares were sold at an average price of $5.16, for a total value of $101,177.28. Following the transaction, the chief executive officer owned 1,286,500 shares of the company’s stock, valued at $6,638,340. This represents a 1.50% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 55,428 shares of company stock worth $296,508. 7.10% of the stock is currently owned by insiders.
Hedge Funds Weigh In On Abeona Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of the company. AIGH Capital Management LLC bought a new stake in Abeona Therapeutics in the 3rd quarter valued at about $15,225,000. AWM Investment Company Inc. acquired a new position in Abeona Therapeutics during the 2nd quarter valued at about $9,184,000. Nan Fung Trinity HK Ltd. boosted its stake in Abeona Therapeutics by 336.6% during the 3rd quarter. Nan Fung Trinity HK Ltd. now owns 552,270 shares of the biopharmaceutical company’s stock valued at $2,899,000 after purchasing an additional 425,770 shares during the period. Simplify Asset Management Inc. bought a new position in Abeona Therapeutics in the 3rd quarter worth about $1,451,000. Finally, Bank of New York Mellon Corp bought a new position in Abeona Therapeutics in the 2nd quarter worth about $1,262,000. Institutional investors and hedge funds own 80.56% of the company’s stock.
Key Abeona Therapeutics News
Investors following ABEO have been watching these news items:
- Positive Sentiment: HC Wainwright raised its FY2026 EPS estimate to a loss of $0.96 from a loss of $1.15, and its Q4 2026 estimate to a loss of $0.22 from $0.24. The firm reiterated its Buy rating. MarketBeat analyst estimates
- Neutral Sentiment: Wall Street Zen raised its rating on ABEO to Hold, a less cautious stance that nevertheless does not signal a Buy recommendation. Abeona Therapeutics Stock Bumped Up to Hold by Wall Street Zen
- Negative Sentiment: A separate report noted falling fair-value expectations as concerns grow about the pace of Zevaskyn’s commercial ramp, a potential headwind to the stock. Abeona Therapeutics Stock Sees Fair Value Falls As Zevaskyn Ramp Concerns Grow
Abeona Therapeutics Company Profile
Abeona Therapeutics, Inc. is a biotechnology company focused on developing cell and gene therapies for serious and rare diseases. Its work includes treatments designed to address the underlying genetic causes of disease. The company’s lead product, ZEVASKYN (prademagene zamikeracel), is an autologous gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa, a rare inherited skin disorder. Made from a patient’s skin cells, the therapy uses genetic modification to help cells produce type VII collagen and is applied to wounds.
See Also
- Five stocks we like better than Abeona Therapeutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
